Immunocore reports Phase I data for IMCgp100 in melanoma

Immunocore Ltd. (Abingdon, U.K.) reported data from 19 evaluable HLA-A2-positive patients with metastatic uveal melanoma in an intra-patient dose-escalation Phase I trial showing that once-weekly IMCgp100 (ImmTAC-gp100) led to an objective response rate (ORR) of 11%, including 2 partial responses, plus 12 cases of stable disease. The median time to response was 27.8 weeks and the median duration of response was 24.1 weeks. Median progression-free survival (PFS) was 24.3 weeks. Additionally, the maximum tolerated dose (MTD) and recommended Phase II dose is once-weekly 75 μg IMCgp100. Data were presented at the American Society of Clinical Oncology meeting in Chicago.

The open-label, U.S. and U.K. trial’s primary endpoint is the MTD and recommended Phase II dose of the intra-patient escalation regimen of IMCgp100. Secondary endpoints include ORR and PFS...